CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE BORDEAUX (France)
INSTITUT POLYTECHNIQUE DE BORDEAUX (France)
Inventeur(s)
Prakasam, Mythili
Largeteau, Alain
Silvain, Jean-François
Abrégé
The present invention relates to a high-pressure method for preparing a metal monolith either as dense or as highly porous form, by rapid inductive heating hot pressing equipment. The method of the invention allows to obtain a metal monolith from metal powder without binder or any other additives
B22F 3/00 - Fabrication de pièces ou d'objets à partir de poudres métalliques, caractérisée par le mode de compactage ou de frittage; Appareils spécialement adaptés à cet effet
B22F 3/11 - Fabrication de pièces ou d'objets poreux
B30B 15/02 - Matrices; Garnitures ou montures appropriées; Moules
B30B 15/34 - Chauffage ou refroidissement des presses ou des parties de presse
C22C 1/05 - Mélanges de poudre métallique et de poudre non métallique
C22C 47/14 - Fabrication d'alliages contenant des fibres ou des filaments métalliques ou non métalliques par métallurgie des poudres, c. à d. par traitement de mélanges de poudre métallique et de fibres ou de filaments
C22C 49/02 - Alliages contenant des fibres ou des filaments métalliques ou non métalliques caractérisés par le matériau de la matrice
C22C 49/14 - Alliages contenant des fibres ou des filaments métalliques ou non métalliques caractérisés par les fibres ou les filaments
2.
NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE MONTPELLIER (France)
UNIVERSITE DE STRASBOURG (France)
Inventeur(s)
Mornat, Pauline
Sokoloff, Pierre
Rognan, Didier
Abrégé
48481436141414142214141414141414144)alkoxy group. The present invention further related to a pharmaceutical composition comprising it and to its use in the prevention and/or the treatment of pain.
C07D 217/02 - Composés hétérocycliques contenant les systèmes cycliques de l'isoquinoléine ou de l'isoquinoléine hydrogénée avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle contenant l'azote; Alkylène-bis-isoquinoléines
C07D 241/42 - Benzopyrazines avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/4725 - Isoquinoléines non condensées, p.ex. papavérine contenant d'autres hétérocycles
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinoxaline, phénazine
A61K 31/502 - Pyridazines; Pyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. cinnoline, phtalazine
3.
METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIÈRE) (France)
SORBONNE UNIVERSITÉ (France)
OSAKA UNIVERSITY (Japon)
Inventeur(s)
Cartier-Lacave, Nathalie
Besnard-Guerin, Corinne
Rousselot, Lisa
Mochizuki, Hideki
Tada, Satoru
Abrégé
The present invention relates to the treatment alpha-synucleinopathies. In this study, the inventors showed that restoring brain cholesterol pathway and defective autophagy by AAV- CYP46A1 delivery, as evidenced in several neurodegenerative pathologies, could be a relevant therapeutic approach in alpha-synucleinopathies and particularly in PD. Thus the present invention relates to a vector for use in the treatment of alpha-synucleinopathies, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE LILLE (France)
NANTES UNIVERSITÉ (France)
UNIVERSITE POLYTECHNIQUE HAUTS-DE-FRANCE (France)
CENTRALE LILLE INSTITUT (France)
Inventeur(s)
Hallot, Maxime
Robert, Kévin
Marlec, Florent
Asbani, Bouchra
Lethien, Christophe
Roussel, Pascal
Bounor, Botayna
Abrégé
A microstructured substrate comprising a main body and a plurality of elongated elementary microstructures extending from the main body, wherein the microstructured substrate comprises a plurality of nanowires positioned on at least one area of the surface of the main body and on the surface of the elementary microstructures that extend from the main body over said area.
H01G 11/26 - Condensateurs hybrides, c. à d. ayant des électrodes positive et négative différentes; Condensateurs électriques à double couche [EDL]; Procédés de fabrication desdits condensateurs ou de leurs composants Électrodes caractérisées par leur structure, p.ex. multicouches, selon la porosité ou les caractéristiques de surface
H01G 11/28 - Condensateurs hybrides, c. à d. ayant des électrodes positive et négative différentes; Condensateurs électriques à double couche [EDL]; Procédés de fabrication desdits condensateurs ou de leurs composants Électrodes caractérisées par leur structure, p.ex. multicouches, selon la porosité ou les caractéristiques de surface agencées ou disposées sur un collecteur de courant; Couches ou phases entre les électrodes et les collecteurs de courant, p.ex. adhésifs
H01M 4/1391 - Procédés de fabrication d'électrodes à base d'oxydes ou d'hydroxydes mixtes, ou de mélanges d'oxydes ou d'hydroxydes, p.ex. LiCoOx
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p.ex. LiMn2O4 ou LiMn2OxFy
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p.ex. LiNiO2, LiCoO2 ou LiCoOxFy
H01M 4/134 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de métaux, de Si ou d'alliages
5.
PRODUCTION OF A LIQUID ORGANIC ELECTROLYTE METAL-ION BATTERY COMPONENT, AND ELECTROCHEMICAL CELL COMPRISING SUCH A COMPONENT
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE AMIENS PICARDIE JULES VERNE (France)
UNIVERSITE DE LILLE (France)
ECOLE NATIONALE SUPERIEURE DES ARTS ET INDUSTRIES TEXTILES (France)
Inventeur(s)
Maurel, Alexis
Grugeon, Sylvie
Dupont, Loïc
Panier, Stéphane
Cayla, Aurélie
Gomes, Luisa Larissa Arnaldo
Boudeville, Victor
Abrégé
The subject matter of the present invention is a method for producing such components, the components that can be obtained by this method and the use of these components in the production of a liquid organic electrolyte electrochemical cell.
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p.ex. liants, charges
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
H01M 50/414 - Résines synthétiques, p.ex. thermoplastiques ou thermodurcissables
H01M 50/446 - Matériau composite constitué d’un mélange de matériaux organiques et inorganiques
6.
CATALYST SYSTEM BASED ON AN IRON COMPLEX AND USE THEREOF FOR THE POLYMERIZATION OF CONJUGATED DIENES
COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE SUPÉRIEURE DE CHIMIE PHYSIQUE ELECTRONIQUE DE LYON (France)
INSTITUT NATIONAL DES SCIENCES APPLIQUÉES DE LYON (France)
UNIVERSITE CLAUDE BERNARD LYON 1 (France)
Inventeur(s)
Vaultier, Florent
Hall, Nicolas
Monteil, Vincent
Raynaud, Jean
Abrégé
22120320620312032062020 aromatic radical, which may be substituted or unsubstituted; for the polymerization of conjugated dienes, in particular the stereospecific polymerization of 1,3-dienes, especially butadiene and isoprene.
C08F 4/70 - Métaux du groupe du fer, métaux du groupe du platine ou leurs composés
C08F 136/04 - Homopolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, l'un au moins contenant plusieurs liaisons doubles carbone-carbone le radical ne contenant que deux doubles liaisons carbone-carbone conjuguées
7.
METHOD FOR MEASURING AND PROCESSING OF THERMOGRAPHY DATA
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (France)
ECOLE NORMALE SUPERIEURE DE LYON (France)
UNIVERSITE GRENOBLE ALPES (France)
Inventeur(s)
Chaput, Frederic
Lerouge, Frederic
Karpati, Szilvia
Bulin, Anne-Laure
Abrégé
Disclosed are crystalline hafnium oxide nanoparticles, a method for manufacturing same, and the uses thereof. The invention relates to crystalline hafnium oxide nanoparticles, characterized in that they bear amide molecules and/or at least one amide degradation product chosen from a carboxylic acid, an amine or an amino acid and/or residues of said molecules on their surface.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
FONDATION IMAGINE (France)
UNIVERSITÉ PARIS CITÉ (France)
Inventeur(s)
Viau, Amandine
Bienaime, Frank
Ferri, Giulia
Saunier, Sophie
Abrégé
Chronic nephropathies, in particular tubulointertial nephropathy or tubulointertial nephropathy with fibrosis feature represent a real global public health concern. In particular, nephronophthisis (NPH) is an orphan genetic disease affecting the kidney. This recessive affection usually manifests with polyuria followed by a gradual reduction in kidney function related to progressive renal scarring. To date, no treatment is available for this affection. Now the inventors show that inhibition of the Hippo signalling pathway represents a new therapeutic avenue for the treatment of chronic nephropathies such as NPH. In particular, the inventors show that inhibition of MST1/2 or LATS1/2 reduces the NPH pro-inflammatory signature in mIMCD-3 renal cells even in response to uropathogenic bacteria. Thus the present invention relates to use of inhibitors of the Hippo signalling pathway for the treatment of chronic nephropathies.
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
10.
PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
SORBONNE UNIVERSITE (France)
Inventeur(s)
Abada, Zahra
Martin-Mingot, Agnès
Bleriot, Yves
Thibaudeau, Sébastien
Abou-Hassan, Ali
Abrégé
The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.
C07D 209/08 - Indoles; Indoles hydrogénés avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone de l'hétérocycle
C07C 311/00 - Amides d'acides sulfoniques, c. à d. composés comportant des atomes d'oxygène, liés par des liaisons simples, de groupes sulfoniques remplacés par des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso
C07D 211/14 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux ne contenant que des atomes de carbone et d'hydrogène liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
C07D 211/38 - Atomes d'halogènes ou radicaux nitro
C07D 215/06 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle comportant uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
C07D 519/04 - Alcaloïdes de dimères d'indole, p.ex. vincaleucoblastine
C07D 213/12 - Préparation par cyclisation utilisant de l'ammoniac, des amines, des sels d'amines ou des nitriles à partir de composés non saturés
C07C 209/74 - Préparation de composés contenant des groupes amino liés à un squelette carboné à partir d'amines, par des réactions n'impliquant pas de groupes amino, p.ex. réduction d'amines non saturées, aromatisation ou substitution du squelette carboné par halogénation, halogénhydratation, déshalogénation ou déshalogénhydratation
C07C 303/40 - Préparation d'esters ou d'amides d'acides sulfuriques; Préparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par des réactions n'impliquant pas la formation de groupes sulfonamide
11.
HYBRID SOLID ELECTROLYTE WITH REDUCED POLYMER/CERAMIC INTERFACIAL STRENGTH
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ SAVOIE MONT BLANC (France)
Inventeur(s)
Pavlenko, Ekaterina
Jordy, Christian
Bouchet, Renaud
Mangani, Léa
Isaac, James
Devaux, Didier
Abrégé
The present application relates to ceramic/polymer hybrid solid electrolytes with improved interfacial strength, comprising a surface-dehydrated pre-treated ceramic.
H01M 10/056 - Accumulateurs à électrolyte non aqueux caractérisés par les matériaux utilisés comme électrolytes, p.ex. électrolytes mixtes inorganiques/organiques
H01M 6/18 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments primaires; Leur fabrication Éléments avec électrolytes non aqueux avec électrolyte solide
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Annereau, Maxime
Dowek, Antoine
Legrand, François-Xavier
Rieutord, André
Abrégé
The invention provides a pharmaceutical composition in oral liquid form, comprising vinorelbine, or a pharmaceutically acceptable salt thereof, and a cyclodextrin that is sulfobutylether-beta-cyclodextrin (SBE-beta-CD), preferably wherein at least 95%, vinorelbine, or said pharmaceutically acceptable salt thereof, is in form of an inclusion complex with said cyclodextrin.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
UNIVERSITÉ PARIS CITÉ (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Pendino, Frédéric
Donnadieu, Emmanuel
Fumagalli, Mattia
An, Dongjie
Abrégé
The present invention relates to the adoptive therapy using notably CAR-T cells. Here the inventors used a lentiviral vector approach to silence RINF expression in a shRNA- dependent manner and evaluate the consequences of RINF silencing on human CAR-T cells proliferation ex vivo and their functionality and capacity to eradicate tumor cells in vivo. More, the proposed methodology to improve CAR-T cells persistence and efficacy by disrupting RINF/CXXC5 is not restricted to patients suffering from hematological or solid cancers (anti- CD19, anti-EGFR, anti-BCMA…) but could be also used to improve the efficacy of ACT in non-cancer diseases by such as lupus (1), cardiac fibrosis (2) or aging related-disorders (3). Thus, the present invention relates to an immune cell characterized in that it is defective for RINF.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE MONTPELLIER (France)
ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER (France)
Inventeur(s)
Delavarde, Aliénor
Maillard, Sylvain
Caillol, Sylvain
Pinaud, Julien
Abrégé
The invention primarily relates to a biobased polyurethane resin composition, characterised in that it is obtained by mixing a volume V1 of polyisocyanate phase and a volume V2 of polyol phase, and in that: - either the polyisocyanate phase includes at least two polyisocyanates, at least one of which is an isocyanate-terminated prepolymer that comprises at least 70% biobased carbons and the other comprises at least 60% biobased carbons, and the polyol phase includes at least one polyol that comprises at least 80% biobased carbons, - or the polyol phase includes at least two polyols that each comprise at least 80% biobased carbons, and the polyisocyanate phase includes at least one isocyanate-terminated prepolymer that comprises at least 70% biobased carbons. Preferentially, the number of isocyanate functions in the polyisocyanate phase is equal to the number of alcohol functions in the polyol phase. The invention also relates to a method for manufacturing such a composition, which method advantageously involves evaluating the equivalent reactive volumes of each compound. The invention lastly relates to a printed support at least partially covered with a dome of resin, which dome of resin is produced from said polyurethane resin composition.
C08G 18/10 - Procédés mettant en œuvre un prépolymère impliquant la réaction d'isocyanates ou d'isothiocyanates avec des composés contenant des hydrogènes actifs, dans une première étape réactionnelle
C08G 18/72 - Polyisocyanates ou polyisothiocyanates
C08G 18/79 - Polyisocyanates ou polyisothiocyanates contenant des hétéro-atomes autres que l'azote, l'oxygène ou le soufre de l'isocyanate ou de l'isothiocyanate de l'azote caractérisés par le polyisocyanate utilisé, celui-ci contenant des groupes formés par oligomérisation d'isocyanates ou d'isothiocyanates
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE MONTPELLIER (France)
ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE MONTPELLIER (France)
Inventeur(s)
Pellet-Rostaing, Stéphane
Giusti, Fabrice
Arrachart, Guilhem
Piton, Raphaëlle
Baus-Lagarde, Béatrice
Abrégé
The invention relates to the use of a lipophilic derivative of an aminopolycarboxylic acid as an extractant to extract at least one rare earth from an acidic aqueous solution. Applications: production of rare earths from concentrates derived from urban ores and, in particular, from concentrates from waste electrical and electronic equipment such as used or discarded NdFeB permanent magnets; production of rare earths from concentrates derived from natural ores or from concentrates derived from residues of natural ores.
C22B 3/26 - Traitement ou purification de solutions, p.ex. de solutions obtenues par lixiviation par extraction liquide-liquide utilisant des composés organiques
C22B 7/00 - Mise en œuvre de matériaux autres que des minerais, p.ex. des rognures, pour produire des métaux non ferreux ou leurs composés
C07C 237/06 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques
16.
ENZYMATIC DEGRADATION OF CRYSTALLIZABLE POLYMERS OR COPOLYMERS AND POST-CONSUMER/POST-INDUSTRIAL POLYMERIC MATERIALS CONTAINING CRYSTALLIZABLE POLYMERS OR COPOLYMERS
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (France)
SORBONNE UNIVERSITE (France)
Inventeur(s)
Garate, Hernan
Leibler, Ludwik
Freymond, Clément
Griffiths, Andrew
Breloy, Louise
Mansaku, Brian
Pallis, Jack
Abrégé
The present disclosure is related to systems and methods of enzymatic degradation of crystallizable polymers or copolymers and PC/IPM containing crystallizable polymers or copolymers.
C08J 11/10 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p.ex. dévulcanisation
C08J 11/06 - Récupération ou traitement des résidus des polymères sans réaction chimique
C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
C12N 9/20 - Scission des triglycérides, p.ex. au moyen de lipase
C12N 9/80 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides aliphatiques
B29B 17/00 - Récupération de matières plastiques ou d'autres constituants des déchets contenant des matières plastiques
B02C 19/00 - Autres dispositifs ou procédés de désagrégation
17.
OPTICAL SUBSTRATE HAVING INTEGRATED ANTENNAS, AND SPECTROMETER COMPRISING SAME
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT POLYTECHNIQUE DE GRENOBLE (France)
UNIVERSITE SAVOIE MONT BLANC (France)
Inventeur(s)
Martin, Guillerme
Morand, Alain
Abrégé
The invention relates to an optical substrate (1) having an integrated waveguide (2), at least one antenna (330) being formed in the optical substrate (1), the at least one antenna being formed by a plurality of nanoholes (341, 342, 343), at least one of the nanoholes (341, 342, 343) differing from the other nanoholes (341, 342, 343) by at least one of: its diameter, its spacing of the waveguide (2) in the height direction of the optical substrate (1), and its distance from an adjacent nanohole of the same antenna in the longitudinal direction of the optical substrate (1). The invention also relates to a spectrometer (S) that integrates an optical substrate (1) of this kind.
G02B 6/12 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES - Détails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p.ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
B82Y 20/00 - Nano-optique, p.ex. optique quantique ou cristaux photoniques
G02B 6/124 - Lentilles géodésiques ou réseaux intégrés
G02B 6/293 - Moyens de couplage optique ayant des bus de données, c. à d. plusieurs guides d'ondes interconnectés et assurant un système bidirectionnel par nature en mélangeant et divisant les signaux avec des moyens de sélection de la longueur d'onde
18.
METHOD FOR DETERMINING THE LITHIUM CONTENT IN A BIOLOGICAL FLUID
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ DE FRANCHE-COMTÉ (France)
CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE BESANCON (France)
Inventeur(s)
Wacogne, Bruno
Azzopardi, Charles-Louis
Gauthier-Manuel, Bernard
Charriere, Karine
Abrégé
Method for determining an amount of lithium contained in a biological fluid, said method comprising the steps consisting in adding, to a biological fluid sample of known volume, a given volume of a discriminating solution, the effect of which is to obtain a biological fluid solution buffered at a pH of between 6 and 8 and to bring about precipitation of at least a portion of the cations contained in the biological fluid sample except for the lithium Ions. The method further comprises the steps consisting in depositing a given volume of biological fluid solution onto an active layer (2) of an optode (1), said active layer comprising a chemical transducer of which at least one optical property is modified In the presence of lithium ions in the biological fluid solution, in measuring at least one characteristic of at least one light wave emitted or reflected by the active layer of the optode and in determining, from the at least one measured characteristic and from calibration data, an amount of lithium contained in the biological fluid.
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
G01N 21/82 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un précipité ou une turbidité
19.
COMBINATION OF A BTN3A ACTIVATING ANTIBODY, A BCL2 INHIBITOR AND HYPOMETHYLATING AGENT FOR USE IN TREATING CANCER
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ D'AIX-MARSEILLE (France)
INSTITUT JEAN PAOLI & IRENE CALMETTES (France)
Inventeur(s)
Le Floch, Anne-Charlotte
Olive, Daniel
Vey, Norbert
Frohna, Paul
Wieduwild, Elisabeth
Makadamutil, Loui
Abrégé
The present invention relates a therapeutic combination of a BTN3A activating antibody, a Bcl-2 family inhibitor and hypomethylating agents that is particularly useful for the treatment of cancer, in particular hematological malignancies. The present disclosure more particularly relates to the combined use of a BTN3A activating antibody that activates the cytolytic function of Vγ9Vδ2 T cells, and of Venetoclax, which selectively inhibits the Bcl2 receptor, and hypomethylating agents such as Azacytidine, to promote synergistically and specifically Vγ9Vδ2 T cell anticancer activity.
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p.ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p.ex. sulfadiazine
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (France)
UNIVERSITÉ TOULOUSE III – PAUL SABATIER (France)
Inventeur(s)
Galinier, Anne
Dray, Cédric
Labaste, François
Stephan, Marion
Pey, Vincent
Minville, Vincent
Abrégé
Circulatory failure generates hypoxia and leads to accumulation of reductive species in tissue and circulatory failure monitoring tools are needed but rare. Cardiopulmonary bypass (CPB) is known to promote brief circulatory failure during its initiation. In the present study, the Inventors demonstrate a correlation between whole blood redox potential and circulatory failure during (CPB). They made a prospective study with 17 patients eligible for cardiac surgery with cardiopulmonary bypass. They demonstrated a frank reduction of the whole blood redox potential during circulatory failure during the initiation of CPB. They also demonstrated that they were able to classify patients in 3 groups, one of them presenting an unfavorable post-operative outcome. Accordingly, the present invention relates to a method of diagnosing acute circulatory failure in a patient comprising determining the level of redox potential in a sample obtained from said patient, wherein the level of redox potential indicates whether the patient suffers or not from an acute circulatory failure.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PARIS-SACLAY (France)
Inventeur(s)
Richardt, Isabelle
Moreau, Jérémy
Hamouda, Frédéric
Aassime, Abdelhanin
Abrégé
Deposition of a material such as indium in the form of nitrided thin layers, by evaporation and dual activation using a nitrogen plasma (41) and an electron beam (42).
C23C 14/00 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement
C23C 14/06 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement caractérisé par le matériau de revêtement
C23C 14/26 - Evaporation sous vide par chauffage de la source par induction ou par résistance
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (France)
ECOLE SUP CHIMIE PHYS ELECTRONIQ LYON (France)
Inventeur(s)
Marquette, Christophe
Zaidi, Hamza Raza
Abrégé
The invention relates in particular to a cell culture device comprising an insert (1) having an internal cavity (11) delimited by an insert side wall (12) and an insert bottom (10), said internal cavity being able to receive said cell culture in a cell culture fluid so as to create a cell tissue (2). The device comprises a container (3) that removably receives said insert, said side wall (12) having first through-holes (13). The container comprises an internal flue (30) and an opening (33) which allows said insert (1) to be inserted into said flue. The insert bottom comprises second through-holes (14) allowing observation of the cells therethrough, said first and second through-holes being capillary holes able to retain said cell culture fluid in said internal cavity and serving to anchor said cell tissue.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
THE TRUSTEES OF PRINCETON UNIVERSITY (USA)
Inventeur(s)
Pupillo, Guido
Jandura, Sven
Thompson, Jeffrey
Abrégé
A method for optimizing a quantum operation to be applied on two quantum objects of a system of quantum objects The present invention relates to a method for optimizing a quantum operation to be applied on at least two quantum objects (12) of a system (10) of quantum objects, the method comprising the determination of an optimized pulse to be generated by at least one controlled laser for implementing the quantum operation on the at least two quantum objects (12) while fulfilling a robustness criterion, the at least two quantum objects (12) having a quantum state depending on the excitation level of the at least two quantum objects, the excitation level being chosen between 01, 10 and 11, 0 defining a de-excited state for a quantum object and 1 defining an excited state for a quantum object, the quantum state having a zero order term and a first order term.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
24.
OPTICAL DEVICE FOR SELF-REFERENCED FULL-FIELD TEMPORAL OPTICAL COHERENCE TOMOGRAPHY MICROSCOPIC IMAGING, AND ASSOCIATED FACILITY AND METHOD
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (France)
CENTRE HOSPITALIER D'OPHTALMOLOGIE DES QUINZE-VINGTS (France)
Inventeur(s)
Grieve, Kate
Thouvenin, Olivier
Monfort, Tual
Azzollini, Salvatore
Reichman, Sacha
Abrégé
The invention relates to an optical device for the full-field optical coherence tomography microscopic imaging of at least one sample, the device comprising a lens for observing the sample when in use, the device comprising a specular interface, the device thus being able, when in use, to allow the production of at least one interference between at least one reference wave obtained by the reflection of light emitted by a light source associated with the device from the specular interface, and at least one object wave obtained by the backscattering of the light emitted by the source from the sample, the specular interface being arranged with respect to the lens in such a way that, when in use, the object wave passes through the specular interface on its path between the sample and the source. The invention also relates to the corresponding facility and method.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CENTRALESUPELEC (France)
SAFRAN ELECTRONICS & DEFENSE (France)
Inventeur(s)
Pouilly-Cathelain, Maxime
Feyel, Philippe
Attrazic, Yannick Ghislain Sébastien Xavier
Duc, Gilles
Sandou, Guillaume
Abrégé
One aspect of the invention relates to a method (100) for controlling a mechatronic system, based on a model for predicting the behaviour of the mechatronic system and a cost function ensuring compliance with constraints by the mechatronic system, with a view to following path instructions to a prediction horizon, the method comprising: reformulating (10) the constraints into barrier functions and integrating the barrier functions into the cost function; and for each sampling period of a sequence of sampling periods: obtaining (20) the path instructions and at least one measurement of the mechatronic system in a current state; determining (30) coefficients of a polynomial of order m using a Nelder-Mead method optimizing the cost function based on the predicting model, this determining step receiving as input the path instructions and the at least one measurement of the mechatronic system obtained (20); computing (40) a command through evaluation of the polynomial; and applying (50) the command to the mechatronic system.
G05B 13/02 - Systèmes de commande adaptatifs, c. à d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques
G05B 13/04 - Systèmes de commande adaptatifs, c. à d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques impliquant l'usage de modèles ou de simulateurs
26.
THERAPY BY TRANS-SPLICING OF OPA1 PRE-MESSENGER RNAS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OPA1 GENE MUTATIONS
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
UNIVERSITE TOULOUSE III-PAUL SABATIER (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (France)
Inventeur(s)
Espagnolle, Nicolas, Lucien
Gadelorge, Mélanie, Alexandra
Corre, Jill
Abrégé
The present invention relates to the method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing stem cells/mesenchymal stromal cells, endothelial progenitors and primary plasma cells of one or more MM patients. The present invention also relates to the spheroids obtained by said method, and uses thereof.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (France)
UNIVERSITE PARIS CITE (France)
Inventeur(s)
Couture, Olivier
Hingot, Vincent
Denis, Louise
Aissani, Abderrahmane
Bodard, Sylvain
Correas, Jean-Michel
Abrégé
The present invention relates to a method for ultrasound imaging of a microvascular structure, which method characterised in that it comprises: - a step of injecting ultrasound contrast agents into blood vessels in a region comprising a microvascular structure, - a step of ultrasound imaging the region comprising the microvascular structure while the contrast agents flow through the blood vessels, the concentration of the contrast agents and/or the ultrasound frequency of the imaging being chosen such that the contrast agents are sufficiently separated to prevent feedback, - a step of detecting/filtering and locating the contrast agents, - a step of individually monitoring the contrast agents, - a step of classifying the behaviours of the individually monitored contrast agents according to at least one predetermined behaviour characteristic of contrast agents flowing through the microvascular structure, and - a step of imaging the microvascular structure according to the thus-performed classification.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS (France)
SORBONNE UNIVERSITÉ (France)
UNIVERSITÉ PARIS CITÉ (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Poulet, Geoffroy
Galichon, Pierre
Anglicheau, Dany
Taly, Valérie
Péré, Hélène
Veyer, David
Laurent-Puig, Pierre
Beinse, Guillaume
Abrégé
The present invention relates to a kit and an in vitro method for detecting and characterizing the degradation of a particular organ or tissue, on the basis of the analysis of the presence of at least one specific methylated cell-free DNA in a biological sample. More particularly, the invention relates to a kit and a method for detecting and characterizing the degradation of an organ selected from: the brain, the lung and the kidney, and/or of a tissue present in this organ. The invention also relates to a method for the in vitro diagnosis of a disease or condition involving the lysis of an organ or tissue.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G01N 21/77 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique
C01G 15/00 - Composés du gallium, de l'indium ou du thallium
G01N 33/84 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des composés inorganiques ou le pH
G01N 21/70 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité mécaniquement, p.ex. par triboluminescence
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
31.
METHOD AND DEVICE FOR ASSISTING THE DETERMINATION OF AN ANTIOXIDANT DOSAGE FOR A PERSON SUFFERING FROM OXIDATIVE STRESS
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER (France)
Inventeur(s)
Laoudj-Chenivesse, Dalila
Abrégé
The invention relates to a method (100) for assisting the determination of a dosage of antioxidants to be administered to a patient suffering from oxidative stress, said method (100) comprising at least one iteration of a prediction phase (108) comprising the following steps: - measurement (110), on a blood sample previously taken from said patient, of a level of at least the following input parameters: cholesterol level, zinc level, copper level, vitamin C level, vitamin E level, and selenium level; - estimation (130) of a dosage for at least one antioxidant to be administered to said patient, via a previously trained estimation model, executed by a calculation unit, said estimation model taking as input said at least one input parameter. The invention also relates to a device which implements such a method.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
32.
- DEVICE AND METHOD FOR CHARACTERIZING CELLS SUBJECTED TO A PHYSICAL STRESS
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ CLAUDE BERNARD LYON 1 (France)
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (France)
ECOLE SUP CHIMIE PHYS ELECTRONIQ LYON (France)
Inventeur(s)
Courtial, Edwin-Joffrey
Petiot, Emma
Maleki, Mehdi
Halima, Imen
Frossard, Gabriel
Abrégé
The present invention relates to a microfluidic device and to a method for applying at least one hydrodynamic stress of defined intensity and duration to cells in suspension, said cell being in motion in said device, and for characterizing the morphology and the physiological state of these cells during, and optionally after, the application of the hydrodynamic stress.
G01N 15/14 - Recherche par des moyens électro-optiques
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p.ex. magnétisme, ondes sonores
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
33.
METHOD FOR PRODUCING ONE OR SEVERAL SHARED CANCER EPITOPE(S) DERIVED FROM ALTERNATIVE TRANSLATIONAL CONTROL
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Depil, Stéphane
Baulu, Estelle
Chuvin, Nicolas
Diaz, Jean-Jacques
Marcel, Virginie
Dalla Venezia, Nicole
Abrégé
The present invention relates to a method for producing or identifying one or several shared cancer epitope(s), as well as peptides comprising or consisting of the epitopes identified or produced by said method, expression vectors encoding said peptides, cytotoxic T lymphocytes (CTLs) generated in vitro by stimulation of T cells with the said peptides or vectors, CTLs of a subject treated with said peptides or vectors, and engineered T cells expressing T-cell receptors recognizing said peptides. The present invention also relates to the use of said peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular, the use of said peptides, expression vectors, CTLs, or engineered T cells for preventing or treating at least one cancer in a subject in need thereof.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PARIS CITE (France)
UNIVERSITE PARIS-SACLAY (France)
Inventeur(s)
Michel, Laurence
Sintès, Maxime
Albert, Claire
Agnely, Florence
Beladjine, Mohamed Amine
Huang, Nicolas
Tsapis, Nicolas
Haine Hablal, Liasmine
Abrégé
Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
A61K 31/515 - Acides barbituriques; Leurs dérivés, p.ex. pentobarbital sodique
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p.ex. cholécalciférol, vitamine D3
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ DE MONTPELLIER (France)
ENSCM - ECOLE NATIONALE SUPERIEURE DE CHIMIE (France)
Inventeur(s)
Montheil, Titouan
Cassenti, Thomas
Subra, Gilles
Mehdi, Ahmad
Poncet, Thierry
Abrégé
The present invention relates to a process for tanning hides using a tanning solution that comprises a silicon compound and is free from metals. The invention also relates to a method for preparing leather that includes a tanning process of this type. The invention also relates to tanned hides obtained by such a tanning process. The invention further relates to a process for detanning the hides obtained by means of the above tanning process.
B01D 53/02 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p.ex. chromatographie préparatoire en phase gazeuse
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
38.
ELEMENTARY PARTICLE DETECTOR AND ASSOCIATED DETECTION METHOD
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Laktineh, Imad
Abrégé
The invention relates to an elementary particle detector (1) comprising: dynodes (10) capable of converting an elementary particle into an avalanche of electrons; conductive grids (30) through which accelerated electrons are able to pass, each grid being defined by a unique electric potential, each unique electric potential being chosen so that the unique electric potential of said conductive grid (30) is strictly lower than the unique electric potential applied to the conductive grid (30) immediately thereafter in the direction of detection (X); at least one signal sensor (50) able to measure an electric signal (S) produced by the accelerated electrons when they pass through the conductive grids (30); and a control unit (90) configured to determine, on the basis of the electric signal (S), a conversion dynode (18) at which the conversion of the elementary particle has taken place. The invention further relates to an elementary particle detection method.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
SORBONNE UNIVERSITÉ (France)
UNIVERSITÉ PARIS CITÉ (France)
ÉCOLE NORMALE SUPÉRIEURE (France)
Inventeur(s)
Bensimon, David
Ducos, Bertrand
Scerbo, Pierluigi
Abrégé
The invention relates to a process for programing a single cell or a group of cells to become malignant, comprising the following steps a) providing cell(s) with the following features: o expressing a dedifferentiation factor, and o comprising an oncogene whose expression is inducible, and b) inducing the expression of said oncogene.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CLERMONT AUVERGNE INP (France)
CENTRE HOSPITALIER UNIVERSITAIRE DE CLERMONT-FERRAND (France)
Inventeur(s)
Bartoli, Adrien
Dousse, Robin
Calvet, Lilian
Samarakoon, Prasad
Abrégé
The invention relates to a method for bringing a virtual three-dimensional model of a target organ, which model is called the 3D model, into register with at least one image of said target organ in a scene, said image being obtained by an endoscope (12), the method in particular comprising: a step of predicting a position and orientation of the target organ relative to the scene; a step of superposing at least one current endoscope image with a see-through projection of the 3D model as a function of the predicted position and orientation, on a display device (18); a step of receiving a command indicating an alignment between the see-through projection of the 3D model and the image of the target organ in the current image; and a step of computing the position and orientation of the target organ in the current image relative to the scene.
G06T 7/33 - Détermination des paramètres de transformation pour l'alignement des images, c. à d. recalage des images utilisant des procédés basés sur les caractéristiques
41.
BLUETOOTH TRANSMISSION FROM A SATELLITE TO A GROUND TELECOMMUNICATION TERMINAL
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CYMOON (France)
Inventeur(s)
Ferre, Guillaume
Lattes, Philippe
Abrégé
Device (10) capable of being installed on a satellite (1), comprising telecommunication means (13) for broadcasting information directly to at least one telecommunication terminal (2) on the ground. The information is broadcast according to a Bluetooth Low Energy protocol, and in AD mode. The device can be used in particular for an Earth observation satellite.
H04W 4/06 - Répartition sélective de services de diffusion, p.ex. service de diffusion/multidiffusion multimédia; Services à des groupes d’utilisateurs; Services d’appel sélectif unidirectionnel
H04W 4/90 - Services pour gérer les situations d’urgence ou dangereuses, p.ex. systèmes d’alerte aux séismes et aux tsunamis
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PAUL SABATIER TOULOUSE III (France)
Inventeur(s)
Rousselle, Mélanie, Laura, Josépha
Fradet, Guillaume
Estournes, Claude, Gilbert, Jean-Pierre
Ansart, Florence
Herisson De Beauvoir, Thomas
Abrégé
The invention relates to a method for producing an abradable ceramic composite coating on a substrate, the method comprising: obtaining (E1) a composition (30) in powder form comprising a matrix powder and a ceramic filler hydrated precursor powder having a lamellar crystallographic structure, wherein the ceramic filler powder represents from 5 to 40% of the combined volume of the matrix powder and the ceramic filler powder; compressing the prepared powder composition at a pressure greater than 150 MPa; and a step of reactive sintering (E2) the obtained powder composition, during which the pressure is maintained at a temperature of less than 550°C, and the particles of the matrix powder in the sintered powder composition have an aspect ratio of 2 or greater. The invention also relates to an abradable ceramic coating obtained according to the method. The invention also relates to a superalloy part for a turbomachine, for example a turbine part, comprising such a coating.
C04B 41/89 - Revêtement ou imprégnation pour obtenir au moins deux revêtements superposés de compositions différentes
B32B 18/00 - Produits stratifiés composés essentiellement de céramiques, p.ex. de produits réfractaires
F01D 11/12 - Prévention ou réduction des pertes internes du fluide énergétique, p.ex. entre étages pour obturations de l'espace entre extrémités d'aubes du rotor et stator utilisant un élément de friction allongé, p.ex. un élément d'usure, déformable ou contraint de façon élastique
C23C 24/08 - Revêtement à partir de poudres inorganiques en utilisant la chaleur ou une pression et la chaleur
F01D 25/00 - "MACHINES" OU MACHINES MOTRICES À DÉPLACEMENT NON POSITIF, p.ex. TURBINES À VAPEUR - Parties constitutives, détails ou accessoires non couverts dans les autres groupes ou d'un intérêt non traité dans ces groupes
C04B 111/00 - Fonction, propriétés ou utilisation des mortiers, du béton ou de la pierre artificielle
43.
METHOD FOR TREATING PROSTATE CANCER AND OTHER EPITHELIAL CANCERS
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
UNIVERSITÉ DE MONTPELLIER (France)
INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ LIBANAISE (Liban)
Inventeur(s)
Julien, Eric
Alhourani, Fatima
Patouillard, Julie
Aboumerhi, Raghida
Ribeyre, Cyril
Baldin, Véronique
Pourquier, Philippe
Abrégé
The present invention relates to the treatment of cancer. Here, the inventors identified a subset of prostate cancer patients showing an up-regulation of the epigenetic enzymes SUV4-20H1 and SUV4-20H2, two methyltransferases responsible for the di- and tri- methylation of histone H4 at lysine 20 (H4K20me2/3). Consistent with this, the inventors demonstrate that the pharmacological inhibition of both SUV4-20H1 and SUV4-20H2 enzymes by the chemical compound A196 (14) leads to the complete loss of H4K20me2/3 states in prostate cancer cells. Although displaying epigenetic reprograming at genome-wide levels, cancer cells display any significant impairment in their survival or proliferation, thereby demonstrating that the inhibition of SUV4-20H1 and SUV4-20H2 is not toxic per se. Yet, the inventors showed that the pharmacological inhibition of SUV4-2H1 and SUV4-20H2 subtly affects DNA repair mechanisms and the levels of trapped topoisomerase II (TOPO2) complex in silent chromatin regions upon TOPO2 poisons. This creates in vitro as well as in vivo a lethal synergy between A196 and the TOPO2-poison etoposide in prostate cancer cells. Altogether, the results of the inventors showed that the simultaneous inhibition of SUV4-20H and TOPO2 enzymatic activity constitutes indeed a new therapeutic approach for the treatment of advanced or metastatic prostate cancers, which are particularly addicted to SUV4-20H2 and TOPO2 activities. Other cancers could also benefit of this drug combination, since the co-treatment of A196 and etoposide induces similar lethal synergy in other epithelial cancer cells such as breast cancer cell lines. Thus, the present invention relates to a combination of a SUV4-20H inhibitor and a TOPO2 inhibitor for use in the treatment of a cancer in a subject in need thereof.
A61K 31/136 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p.ex. benzène-amine
A61K 31/501 - Pyridazines; Pyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE SUPERIEURE DE CHIMIE PHYSIQUE ELECTRONIQUE DE LYON (France)
UNIVERSITE CLAUDE BERNARD LYON 1 (France)
Inventeur(s)
Boisson, Christophe
D'Agosto, Franck
Dire, Charlotte
Dronet, Séverin
Langlais, Marvin
Ngo, Robert
Jean-Baptiste-Dit-Dominique, François
Abrégé
The invention relates to triblock polymers of formula A-B-C, in which the symbol A represents a polystyrene block, the symbol B represents a statistical copolymer block having a glass transition temperature of less than -10° C, the statistical copolymer comprising units of a 1,3-diene and more than 50 mol % of ethylene units, and the symbol C represents a polyethylene block having a melting temperature higher than 90°C. The triblock polymers according to the invention have good elastic recovery.
C08F 295/00 - Composés macromoléculaires obtenus par une polymérisation utilisant successivement des catalyseurs de types différents sans désactivation du polymère intermédiaire
C08F 297/08 - Composés macromoléculaires obtenus en polymérisant successivement des systèmes différents de monomère utilisant un catalyseur de type ionique ou du type de coordination sans désactivation du polymère intermédiaire utilisant un catalyseur du type de coordination en polymérisant des mono-oléfines
C08L 53/00 - Compositions contenant des copolymères séquencés possédant au moins une séquence d'un polymère obtenu par des réactions ne faisant intervenir que des liaisons non saturées carbone-carbone; Compositions contenant des dérivés de tels polymères
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CENTRE LEON BERARD (France)
UNIVERSITÉ CLAUDE BERNARD - LYON 1 (France)
Inventeur(s)
Marie, Julien
Preto, Samuel
Tarayre, Hélène
Abrégé
Among the strategies allowing cancer cells to escape the immune system, the presence of Transforming growth factor beta (TGF-β) in the tumor micro-environment (TME) is one of the most potent immunosuppressive mechanisms for many types of tumors. Thus, depleting TGF-β is regarded as a promising potent therapeutic approach to fight cancers, regardless of the type of tumor. However, the major impediment for achieving this objective is that TGF-β belongs to the few cytokines that must be activated once secreted. Moreover, a systemic targeting of TGF-β is associated with profound side effects due to TGF-β ability to sustain the homeostasis of numerous tissues. Hence, selectively targeting of TGF-β activation within the TME appears as a rational approach to boost the anti-tumor response and avoid side effects. The integrin αvβ8 expressed on Tregs specifically promotes TGF-β activation and impairs the anti-CD8 T cell response within the TME of different cancers in both mice and humans. The inventors generated anti-β8 chain of αvβ8 integrin (Itgβ8) neutralizing monoclonal antibodies which specifically bind to Tregs and selectively neutralize the ability of Tregs to activate the TGF-β. Thus, the present invention relates to isolated anti-Itgβ8 neutralizing antibodies which specifically binds to β8 chain of αvβ8 integrin (Itgβ8) expressed on Tregs, and their uses for treating cancer.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
46.
USE OF COUMARIN DERIVATIVES AS TOOLS FOR IN VITRO OR EX VIVO DIAGNOSIS OF BACTERIAL EFFLUX
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
47.
DEVICE FOR SPRAYING OZONATED WATER IN AN AGRICULTURAL ENVIRONMENT
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE TOULOUSE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (France)
INSTITUT NATIONAL POLYTECHNIQUE DE TOULOUSE (France)
Inventeur(s)
Canado, Axel
Hebrard, Gilles
Pages, Marielle
Violleau, Frédéric
Dietrich, Nicolas
Abrégé
The invention relates to a device for spraying ozonated water in an agricultural environment, the device comprising a collar defining a dispensing opening (4) for dispensing both water and ozone together, the water being sprayed by a nozzle (10) set back from the opening, the nozzle being supplied from a tank (7) installed with the device, the ozone gas being dispensed via a gas inlet (22) connected to a device for producing and/or storing gas (9, 13) which is also installed with the device, the gas inlet also being set back in the collar such that the collar defines a chamber (28, 29) for confining the ozone gas emitted around the sprayed liquid in order to allow the sprayed liquid to be enriched with dissolved ozone.
B05B 7/04 - Pistolets pulvérisateurs; Appareillages pour l'évacuation avec des dispositifs permettant le mélange de liquides ou d'autres matériaux fluides avant l'évacuation
B05B 1/34 - Buses, têtes de pulvérisation ou autres dispositifs de sortie, avec ou sans dispositifs auxiliaires tels que valves, moyens de chauffage agencés pour influencer la forme de l'écoulement du liquide ou d'autre matériau fluide, p.ex. pour produire une turbulence
A61L 2/22 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet utilisant des substances chimiques des substances à phases, p.ex. des fumées, des aérosols
A61L 9/14 - Désinfection, stérilisation ou désodorisation de l'air utilisant des substances vaporisées ou pulvérisées
B05B 1/04 - Buses, têtes de pulvérisation ou autres dispositifs de sortie, avec ou sans dispositifs auxiliaires tels que valves, moyens de chauffage agencés pour produire un jet, un pulvérisat ou tout autre écoulement de forme ou de nature particulière, p.ex. sous forme de gouttes individuelles de forme plane, p.ex. en forme d'éventail, en forme de lame
48.
METHOD FOR CHARACTERIZING AN ORGAN OF A PATIENT IN A MEDICAL IMAGE
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Vétil, Rebeca
Abi-Nader, Clément
Bône, Alexandre
Rohé, Marc-Michel
Gori, Pietro
Bloch, Isabelle
Abrégé
The invention relates to a method implemented by computer means for characterizing at least one organ of a patient in at least one medical image, said method comprising the following iterative steps of: segmenting (6) said organ in at least one image (7) representing a healthy organ, so as to obtain at least one segmentation mask (8) of said healthy organ, generating additional segmentation masks of said healthy organ, using at least one data augmentation method (9) on the basis of the segmentation mask obtained in step (a), said data augmentation method (9) being a shape-preserving method, training an autoencoder (10) with the segmentation mask obtained in step (a) and the additional segmentation masks obtained in step (b) to encode the shape of said organ in a latent space (11 ).
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE CLAUDE BERNARD LYON 1 (France)
ECOLE SUPERIEURE DE CHIMIE, PHYSIQUE, ELECTRONIQUE DE LYON - CPE LYON (France)
Inventeur(s)
Eid, Nadim
Devisme, Samuel
Bonnet, Anthony
Fevrier, Thibaut
Lansalot, Muriel
D'Agosto, Franck
Abrégé
The present invention relates to a process for producing a stable PVDF latex by emulsion polymerization in the absence of fluorinated surfactant, said latex being stabilized by poly(vinyl alcohol) (PVOH).
C08F 261/06 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polymères de monomères contenant de l'oxygène tels que définis dans le groupe sur des polymères d'éthers non saturés
C08L 27/16 - Homopolymères ou copolymères du fluorure de vinylidène
C09D 127/16 - Homopolymères ou copolymères du fluorure de vinylidène
C08L 29/04 - Alcool polyvinylique; Homopolymères ou copolymères d'esters partiellement hydrolysés d'alcools non saturés avec des acides carboxyliques saturés
C08F 2/20 - Polymérisation en suspension utilisant des agents de dispersion macromoléculaires
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
UNIVERSITÉ GRENOBLE ALPES (France)
INSTITUT POLYTECHNIQUE DE GRENOBLE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Savin, Valentin
Goswami, Ashutosh-Kumar
Mhalla, Mehdi
Abrégé
The present invention concerns a method and a system of fault tolerant preparation of quantum polar code states, comprising: -a set of single qubit Pauli measurement circuits (3) configured to prepare an initial quantum system 5 of N = 2n single-qubit states associated to an initial quantum base, -a set of two qubit Pauli measurement circuits (7) configured to recursively prepare a quantum polar code |q2n)s °f codelength N = 2n, wherein at each recursive level k, where k = 1 to n, a set of 2n/2k quantum polar code states ||<72fc) j(k) = 1 to 2n/2k of codelengths 2k, siW referenced by corresponding sets Sj^ of indices comprising first and second sets of frozen indices = [17, ■ ■■, i7(k)} and X7(k) = {(i + !);(/<),..., 27k k)} is prepared, each quantum polar code state |q2k) being prepared by the application of two qubit Pauli measurement P ® P circuits on two equivalent polar code states 2^ ) 01 aanndd belonging to the output of the antecedent recursive level k — 1 and referenced by two corresponding sets of iinnddiicceess
G06N 10/70 - Correction, détection ou prévention d’erreur quantique, p.ex. codes de surface ou distillation d’état magique
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Cailleau, Antoine
Klotz, Alain
Abrégé
The invention relates to an angular positioning module (1) for a positioning system for an optical bench, the angular positioning module (1) comprising: a fixed frame (5); a rotating shaft (7); a rotary motor (11); a transmission device (17) being provided with a pulley (19) mounted on the output rod (13) of the rotary motor (11) so as to be coupled in rotation therewith, with a wheel (21) mounted on the rotating shaft (7) so as to be coupled in rotation therewith, and with a cable wound on the one hand around the pulley (19) and on the other hand around the wheel (21) such that the pulley (19) and the wheel (21) are connected by two separate strands of the cable, the rotation of the pulley (19) causing the winding of a first strand and the simultaneous unwinding of a separate second strand around the pulley (19), and vice versa.
G02B 7/00 - Montures, moyens de réglage ou raccords étanches à la lumière pour éléments optiques
F16H 19/06 - Transmissions comportant essentiellement et uniquement des engrenages ou des organes de friction et qui ne peuvent transmettre un mouvement rotatif indéfini pour convertir un mouvement rotatif en mouvement alternatif et vice versa comportant un organe flexible sans fin
52.
ELECTRICAL ENERGY STORAGE MODULE HAVING INTEGRATED POWER CONVERSION MEANS, AND ELECTRICAL ENERGY STORE INCORPORATING SAME
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CONSERVATOIRE NATIONAL DES ARTS ET METIERS (France)
CY CERGY PARIS UNIVERSITE (France)
SAFT (France)
SORBONNE UNIVERSITE (France)
UNIVERSITE PARIS-SACLAY (France)
ÉCOLE NORMALE SUPÉRIEURE PARIS-SACLAY (France)
Inventeur(s)
Roy, Francis
Boulay, Marc
Peuchant, Thomas
Narbonne, Alexandre
Herpe, David
Labrousse, Denis
Laboure, Eric
Abrégé
The invention relates to an electrical energy storage module (M1-ln) which comprises a plurality of elementary storage cells (C1 to C12). According to the invention, the module comprises at least one cell unit (U1-1, U1-2) including a plurality of elementary storage cells connected in series (C1 to C6; C7 to C12) and integrated power-switching means (P1, S1; P2, S2) dedicated to this cell unit, delivering, between two power output terminals (B1, B2) of the cell unit, a positive DC voltage, a negative DC voltage, a zero voltage or a high impedance state, depending on a command received by the cell unit.
G01N 21/27 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
G01N 21/77 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Pucheault, Mathieu
Zivic, Nicolas
Abrégé
The present invention relates to the use of an aminoborane for the preparation of an alkenylaminoborane from a catalyst-free alkyne or in the presence of a catalyst selected from the group of acids consisting of carboxylic acids, sulfonic acids, sulfuric acid, phosphonic acids, phosphoric acid and hexafluoroisopropanol (HFIP), in particular acetic acid, benzoic acid and 4-(dimethylamino) benzoic acid, methylsulfonic acid, phosphoric acid, trifluoroacetic acid (TFA) and hexafluoroisopropanol (HFIP), and a preparation method therefor.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ TOULOUSE III – PAUL SABATIER (France)
INSTITUT CLAUDIUS REGAUD (France)
Inventeur(s)
Segui, Bruno
Meyer, Nicolas
Levade, Thierry
Montfort, Anne
Andrieu-Abadie, Nathalie
Dufau, Carine
Genais, Matthieu
Jung, Benjamin
Delord, Jean-Pierre
Abrégé
Advanced cutaneous melanoma can be treated by immunotherapy targeting immune check points such as PD-1 and CTL-A4. However, 50% of patients do no respond because of primary or acquired resistance mechanism. Thus, new targets for addressing the treatment of said resistance are highly needed. The inventors show that TNF (Tumour Necrosis Factor) and ceramide metabolism alterations in melanoma cells contribute to melanoma progression and resistance to immunotherapies. In particular, the inventors demonstrate that TNF is a potent modulator of ceramide metabolism and TNF-mediated ceramide metabolism changes contribute to various biological processes such as cell proliferation, cell death and cell differentiation. Among the biological processes by which TNF triggers melanoma immune escape and resistance to immunotherapies, TNF triggers a dedifferentiation process of melanoma cells associated with the reduction of melanocytic antigen expression and epithelial to mesenchymal transition. Finally, the inventors show that glycosphingolipid pattern in plasma can predict the clinical outcome of advanced melanoma treated with ipilimumab and nivolumab. Accordingly, ceramide metabolites and metabolizing-enzymes can be new therapeutic targets and/or biomarkers in advanced melanoma patients treated with immunotherapies.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE LORRAINE (France)
Inventeur(s)
Lopes, Sandrine
Legrand, William
Desjardins, Matthieu
Montaigne, François
Lacour, Daniel
Hehn, Michel
Abrégé
The invention relates to a magnetic component comprising a substrate (6) supporting at least one pair of permanent magnets (2) extending in a first direction (X), each magnet (2) having an interaction end (21a, 21b), the interaction ends (21a, 21b) being arranged facing one another, the pair of magnets (2) being arranged so as to exert an antisymmetric magnetic field with a high magnetic field gradient along a second direction (Z) orthogonal to the first direction (X), under the effect of a magnetic field produced by external magnetic means.
H01F 41/34 - Appareils ou procédés spécialement adaptés à la fabrication ou à l'assemblage des aimants, des inductances ou des transformateurs; Appareils ou procédés spécialement adaptés à la fabrication des matériaux caractérisés par leurs propriétés magnétiques pour appliquer un matériau conducteur, isolant ou magnétique sur une pellicule magnétique selon des configurations particulières, p.ex. par lithographie
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
57.
METHOD FOR CHARACTERISING THE DEFORMABILITY OF CELLS OR A PORTION OF CELLS IN A CELL SAMPLE
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Barakat, Abdul
Leclech, Claire
Roellinger, Bettina
Abrégé
The invention relates to a method for characterising the deformability of cells or a portion of cells in a sell sample, the method comprising: • - culturing the cells on a microstructured plate having microgrooves with a predetermined width and depth for at least partially engaging the nuclei of the cells in one or more microgrooves, at least one portion of the surface of the microgrooves being a cell adhesion surface; • - measuring a fluorescence signal of the nuclei, which nuclei are pre-treated so as to emit fluorescence radiation; • - on the basis of the fluorescence signal measured for each nucleus, determining a fluorescence intensity profile and at least one morphological parameter of the nucleus; • - on the basis of the fluorescence intensity profile and the at least one morphological parameter, determining a deformation class of the nucleus in the depth of the microgrooves.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT POLYTECHNIQUE DE BORDEAUX (France)
ECOLE NATIONALE SUPERIEURE D'ARTS ET METIERS (ENSAM) (France)
Inventeur(s)
Achchaq, Fouzia
Legros, Philippe
Abrégé
A thermal energy storage device (1) comprises a storage unit, formed by a reservoir (3) for receiving a thermal energy storage material (5) and a closure device (2) configured to close the opening of the reservoir, and a sealing system for sealing the storage unit, said thermal energy storage material (5) consisting of anhydrous lithium hydroxide having a purity greater than 96% or lithium hydroxide monohydrate with a purity greater than 56%.
F28D 20/02 - Appareils ou ensembles fonctionnels d'accumulation de chaleur en général; Appareils échangeurs de chaleur de régénération non couverts par les groupes ou utilisant la chaleur latente
C09K 5/06 - Substances qui subissent un changement d'état physique lors de leur utilisation le changement d'état se faisant par passage de l'état liquide à l'état solide, ou vice versa
59.
USE OF PLASMONIC INK COMPOSITION ON SYNTHETIC PAPER
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Caffier, Guillaume
Mougin, Karine
Ghellal, Feriel
Spangenberg, Arnaud
Abrégé
In a first aspect, the present disclosure relates to a kit of parts, wherein the kit of parts may comprise a writing instrument comprising a plasmonic ink composition; and a synthetic paper.
ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (France)
SORBONNE UNIVERSITE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Klimenko, Alexandra
Blondeau, Christophe
Joly, Michèle
Ding, Lei
Abrégé
12344 are independently a hydrogen atom or an alkyl group, A is an alkylene group, and the total number of carbon atoms in the surfactant compound of formula (I) is from 10 to 24.
B65G 5/00 - Emmagasinage des fluides dans des excavations ou cavités naturelles ou artificielles souterraines
E21B 41/00 - Matériel ou accessoires non couverts par les groupes
C09K 8/584 - Compositions pour les méthodes de récupération assistée pour l'extraction d'hydrocarbures, c. à d. pour améliorer la mobilité de l'huile, p.ex. fluides de déplacement caractérisées par l'utilisation de tensio-actifs spécifiques
C09K 8/594 - Compositions utilisées en combinaison avec du gaz injecté
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
SORBONNE UNIVERSITE (France)
Inventeur(s)
Dumas, Simon
Descroix, Stéphanie
Lemahieu, Grégoire
Abrégé
The invention relates to a method of extracting a bead from a droplet, comprising the steps of: – providing a droplet of a first fluid within a second fluid, the first fluid being immiscible with the second fluid, the droplet containing a bead; – passing the droplet through a constriction in a main channel, and supplying a third fluid second fluid immiscible with the first fluid in a downstream channel, downstream of the constriction so as to extract the bead from the droplet.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE RENNES (France)
NANTES UNIVERSITÉ (France)
CENTRALESUPELEC (France)
Inventeur(s)
Boryskin, Artem
Ziane, Massinissa
Sauleau, Ronan
Zhadobov, Maxim
Abrégé
The invention relates to a device and method for measuring an electromagnetic dosimetric quantity received by an object illuminated by an electromagnetic (EM) field (23) emitted by an electromagnetic source (2), comprising: - a screen (3) comprising a top surface (31) faced to the electromagnetic source (2) and a bottom surface (32) opposite to the top surface (31 ), said screen (3) being adapted to absorb at least a portion of the EM field emitted by the electromagnetic source (2); - the screen comprising a plurality unit cells (33); - at least one thermal sensor (5) arranged relative to the bottom surface of the screen (3) and configured to measure a physical quantity relative to the heat distribution along a surface of the screen induced due to the absorption of the electromagnetic field in the screen medium; - a processing unit (6) linked to the at least one thermal sensor (5) and configured to calculate the electromagnetic dosimetric quantities from the measured heat distribution, the information relative to the EM field emitted by the EM source, and the predetermined EM and thermal properties of the screen.
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE NATIONALE SUPERIEURE DES MINES DE PARIS (France)
PARIS SCIENCES ET LETTRES (France)
SORBONNE UNIVERSITE (France)
Inventeur(s)
Proudhon, Charlotte
Azencott, Chloé-Agathe
Michel, Marc
Heidary, Maryam
Abrégé
The invention relates to methods for determining the methylation profile of DNA sequences of interest and methods for accurately distinguishing between a healthy methylation profile and a cancerous methylation profile, as well as to kits to implement them.
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE BORDEAUX (France)
INSTITUT POLYTECHNIQUE DE BORDEAUX (France)
Inventeur(s)
Cavarroc, Marjorie, Christine
Peigney, Erwan
Aymonier, Cyril
Aubert, Guillaume
Poulon, Angélique, Nadine, Jeanne
Abrégé
The present invention relates to a method for depositing a continuous coating of aluminium oxide on a metal substrate by means of induction heating-assisted pressurised, temperature-controlled chemical deposition, the method comprising a solvothermal synthesis step based on an aluminium oxide precursor dissolved in a water-co-solvent mixture heated by induction to a temperature of between 400°C and 700°C and a pressure of between 1 MPa and 25 MPa. It also relates to a device (100) for depositing an aluminium oxide on a metal substrate (104) by means of pressurised, temperature-controlled chemical deposition, which device comprises: - an chamber (102) delimited by walls forming a closed volume (V), the chamber being intended to contain a heated and pressurised fluid, the material of the walls of the chamber being transparent to electromagnetic radiation; - a support (106) transparent to electromagnetic radiation intended to support the metal substrate (104) located inside the chamber; - an induction heating device (109) surrounding the outside of the chamber (102) so as to be able to heat the metal substrate (104) positioned on the support (106); - an inlet (116) located in the upper portion of the chamber (102) and configured to allow a precursor material previously dissolved in water to be added to the chamber (102); - an inlet (120) located in the lower portion of the chamber (102) and configured to allow a fluid to be added to the chamber (102); - at least one outlet (124) configured to purge the volume (V); - a sapphire window (112) arranged in the upper portion of the chamber, allowing the temperature of the metal substrate (104) to be controlled by a bichromatic pyrometer (114) arranged outside the chamber; - a set of polymer seals (200); - a metal assembly (202) rigidly screwed together by metal columns (204) containing a circulating fluid maintained, by a cryostat (206), at a temperature of 20°C.
C23C 18/12 - Revêtement chimique par décomposition soit de composés liquides, soit de solutions des composés constituant le revêtement, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement; Dépôt par contact par décomposition thermique caractérisée par le dépôt sur des matériaux inorganiques, autres que des matériaux métalliques
C01B 13/36 - Méthodes de préparation des oxydes ou hydroxydes en général par réaction de précipitation en solution
C01F 7/448 - Déshydratation de l’oxyde ou de l'hydroxyde d'aluminium, c. à d. toutes les conversions d'une forme en une autre impliquant une perte d’eau par des procédés par voie humide en utilisant une pression superatmosphérique, p.ex. la conversion hydrothermale de la gibbsite en boehmite
65.
NICKEL-BASED SUPERALLOY, SINGLE-CRYSTAL BLADE AND TURBINE ENGINE
ECOLE NATIONALE SUPERIEURE DE MECANIQUE AEROTECHNIQUE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE POITIERS (France)
Inventeur(s)
Menou, Edern
Cormier, Jonathan
Rame, Jérémy
Abrégé
The invention relates to a nickel-based superalloy comprising, in weight percentages, 5.0 to 6.0% aluminium, 6.5 to 8.5% tantalum, 0 to 1.0% titanium, 1.0 to 4.0% cobalt, 5.0 to 8.0% chromium, 0 to 0.5% molybdenum, 3.0 to 4.0% tungsten, 3.75 to 5.75% rhenium, 3.5 to 5.0% platinum, 0.05 to 0.25% hafnium and 0 to 0.15% silicon, the remainder being made up of nickel and inevitable impurities. The invention also relates to a single-crystal blade (20A, 20B) comprising such an alloy and to a turbine engine (10) comprising such a blade (20A, 20B).
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PARIS-SACLAY (France)
Inventeur(s)
Galvao Tizei, Luiz
Auad, Yves
Blazit, Jean-Denis
Tence, Marcel
Kociak, Mathieu
Abrégé
12211; and F. determining a value of the scale factor S and a value of the offset O specific to the measurement of the spectrum of the output beam by means of the spectrometer on the basis of the variations in energy ΔE.
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
INSTITUT POLYTECHNIQUE DE GRENOBLE (France)
UNIVERSITE GRENOBLE ALPES (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Grangeat, Pierre
Comsa, Maria-Paula
Koenig, Anne
Phlypo, Ronald
Abrégé
The invention relates to a method for estimating the content of a gas-of-interest in a medium using a measurement device intended to be placed in contact with the medium, the device extending between a contact face intended to be applied against the medium and a distal end, the device comprising a side wall extending between the contact face and the distal end, and the device comprising: on the contact face, at least one intake opening configured to collect the gas-of-interest emitted by the medium, the intake opening extending through the contact face; a measurement chamber comprising a gas sensor, the gas sensor being configured to measure a concentration of the gas-of-interest flowing through the measurement chamber; a collection chamber (30) connected to the measurement chamber and delimited by the side wall, the collection chamber comprising at least one side opening (34) extending through the side face so as to admit ambient air into the collection chamber.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
A61B 5/083 - Mesure du taux de métabolisme en utilisant un essai respiratoire, p.ex. mesure du taux de consommation d'oxygène
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des capteurs optiques, p.ex. des oxymètres à photométrie spectrale
A61B 5/1477 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p.ex. par des moyens polarographiques non invasifs
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
68.
MULTIMODAL PROBE AND METHOD OF MANUFACTURING THE SAME
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
SORBONNE UNIVERSITE (France)
Inventeur(s)
Dumas, Simon
Descroix, Stéphanie
Vallot, Céline
Perie, Leïla
Moutaux, Eve
Abrégé
The invention relates to a probe comprising a bead, a first binding assembly and a second binding assembly, wherein: – the first binding assembly comprises a first bead-binding portion and a first probe portion, – the second binding assembly comprises a second bead-binding portion, a second probe portion, and a cleavable portion between the second bead-binding portion and the second probe portion, – the first and second bead-binding portions are attached to the bead; – the first probe portion is a portion capable of binding to a first analyte; – the second probe portion is a portion capable of binding to a second analyte.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ PARIS CITÉ (France)
Inventeur(s)
Mangeney, Marianne
Marchais, Maude
Abrégé
ex vivoex vivo method to obtain improved CAR-T cells comprising the following steps i) cultivate T cells obtained from a subject with a FOXO1 inhibitor during a time of 2 to 10 days; ii) transforming the T cells into CAR-T cells thanks to a known method.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ PARIS CITÉ (France)
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (France)
Inventeur(s)
Avouac, Jérôme
Lehuen-Monteiro, Agnès
Lesturgie, Manon
Gonzalez, Virginie
Abrégé
Rheumatoid arthritis (RA) is the most common form of inflammatory rheumatism involving small joints which are the seat for swelling and pain with structural damage, responsible for functional disabilities if no treatment is proposed. The inventors show that circulating MAIT cells were reduced and exhibited an activated and anti-apoptotic phenotype in RA patients compared to healthy controls. MAIT cell levels were also found to be increased in the synovial fluid as compared with the peripheral blood, suggesting that circulating MAIT cell deficiency is due to the migration of MAIT cells into the joint. Severity of arthritis induced by mBSA was reduced in mice depleted in MAIT cells. This data suggest that MAIT cells contribute to exacerbation of arthritis. Thus the present invention relates to the use of an agent capable of inhibiting the activation of MAIT cells for the treatment of rheumatoid arthritis
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
COLLEGE DE FRANCE (France)
SORBONNE UNIVERSITÉ (France)
Inventeur(s)
Mariyappan, Sathiya
Grepin, Elisa
Tarascon, Jean-Marie
Abrégé
The invention relates to a sodium layered oxide of formula I: NaxM1a+i-y-z-nM2b+yM3c+zM4d+nO2, wherein: M1a+, M2b+, M3c+and M4d+ are different transition metal ions or mixtures thereof, x is a number ranging from 0.5 to less than 1; y, z and n are numbers ranging from 0.01 to 0.85; y + z + n is less than 1; a, b, c and d are the respective oxidation number of the transition metal ions M1, M2, M3 and M4, respectively; and the cumulative oxidation state of transition metal ions a*(1-y-z-n)+(b*y)+(c*z)+(d*n) is equal to 4-x; and wherein said sodium layered oxide of formula I is not P2- Na2/3Ni1/4Mn1/2Ti1/6Zn1/12O2, P2-Na2/3Ni1/4Mn1/2Ti1/6Mg1/12O2, or P2-Na2/3Ni1/4Mn1/2Ti1/6Mg1/12O2.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ DE STRASBOURG (France)
SICAT (France)
BLACKLEAF (France)
Inventeur(s)
Duong-Viet, Cuong
Pham, Charlotte
Pham-Huu, Cuong
Truong-Phuoc, Lai
Nhut, Jean-Mario
Ba, Housseinou
Lafue, Yannick
Wambergue, Stéphane
Abrégé
24 244 olefin and/or other hydrocarbons, comprising a step of reaction under direct induction heating, with a metal-free carbon material as defined in anyone of the claims, at temperature less than or equal to 800 °C.
C10B 19/00 - Chauffage électrique des fours à coke
C10B 53/07 - Distillation destructive spécialement conçue pour des matières premières solides particulières ou sous forme spéciale de matières polymères synthétiques, p.ex. pneumatiques
C10G 1/10 - Production de mélanges liquides d'hydrocarbures à partir de schiste bitumineux, de sable pétrolifère ou de matières carbonées solides non fusibles ou similaires, p.ex. bois, charbon à partir de caoutchouc ou de déchets de caoutchouc
H05B 6/10 - Appareils de chauffage par induction, autres que des fours, pour des applications spécifiques
C10B 57/06 - Autres procédés de carbonisation ou de cokéfaction; Caractéristiques générales des procédés de distillation destructive utilisant des charges de composition spéciale contenant des additifs
C10G 1/00 - Production de mélanges liquides d'hydrocarbures à partir de schiste bitumineux, de sable pétrolifère ou de matières carbonées solides non fusibles ou similaires, p.ex. bois, charbon
C10G 15/08 - Craquage des huiles d'hydrocarbures par des moyens électriques, par des vibrations électromagnétiques ou mécaniques, par des radiations particulaires ou avec des gaz surchauffés dans des arcs électriques par des moyens électriques ou par des vibrations électromagnétiques ou mécaniques
H05B 6/06 - Commande, p.ex. de la température, de la puissance
73.
A METHOD FOR CONTROLLING A SYSTEM OF QUANTUM OBJECTS AND ASSOCIATED DEVICE
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ DE STRASBOURG (France)
Inventeur(s)
Whitlock, Shannon
Abrégé
A method for controlling a system of quantum objects and associated device The invention relates to a method for controlling a system (10) of quantum objects (12), the method comprising the following steps: - identifying target quantum object(s) of the system (10) of quantum object(s), and - applying a control signal on at least the target quantum object(s) to realize a controlled quantum operation on the target quantum object(s), the control signal being a standing light wave having an amplitude and a phase, the phase being spatially uniform over some regions of space, the standing light wave being applied such that the position of each target quantum object coincides with a region of spatially uniform phase.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
G01R 33/00 - Dispositions ou appareils pour la mesure des grandeurs magnétiques
G04F 5/14 - Appareils pour la production d'intervalles de temps prédéterminés, utilisés comme étalons utilisant des horloges atomiques
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Caffier, Guillaume
Mougin, Karine
Ghellal, Feriel
Spangenberg, Arnaud
Abrégé
The present application relates to a writing instrument comprising a writing tip and an ink reservoir connected to the writing tip, wherein the ink reservoir is sized to contain at least 100 µl of ink and contains an aqueous gel ink, comprising metal nanoparticles as coloring agent, wherein said metal nanoparticles essentially consist of metal and said metal is chosen from silver, gold, aluminum and/or copper, and a dispersing agent; wherein metal nanoparticles are contained within the aqueous gel ink in an amount of 0.5 – 2.5 wt.-%, relative to the total weight of the ink; and wherein the writing instrument is configured to dispense 150 – 800 mg/100m.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Morel, Daphné
Deutsch, Eric
Tillement, Olivier
Lux, François
David, Laurent
Rossetti, Fabien
Durand, Arthur
Howard, Jordyn
Rosson, Elise
Abrégé
The present disclosure relates to a functionalized polymer, for use in treating a disease correlated with heavy metal-induced toxicity or heavy metal-induced carcinogenicity in a subject in need thereof, wherein said functionalized polymer is soluble in aqueous solution, has a weight average molecular mass between 30 kDa and 5000 kDa, and wherein a part of the monomeric units are functionalized with a chelating moiety, wherein therapeutically efficient amount of said functionalized polymer is administered orally to the subject.
A61K 31/715 - Polysaccharides, c. à d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques; Leurs dérivés, p.ex. éthers, esters
A61K 31/718 - Amidon ou amidon dégradé, p.ex. amylose, amylopectine
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
UNIVERSITÉ D'AIX MARSEILLE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT JEAN PAOLI & IRENE CALMETTES (France)
UNIVERSITE COTE D'AZUR (France)
UNIVERSITÉ DE LILLE (France)
CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE (France)
Inventeur(s)
Soriani, Olivier
Borgese, Mauro-Franck
Rapetti Mauss, Raphaël
Tomasini, Richard
Melnyk, Patricia
Abrégé
Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cells and evaluated Sig-1R implication in stromal cues integration by PCC from signaling transmission to biological outcomes, at the cellular and physiological level. They demonstrated that the loss of Sig-1R in epithelial cells inhibits stromal-induced tumor growth and metastatic process. Thus, the inventors demonstrate that Sig-1R is a key actor of the dialog between stromal and cancer cell compartments The present invention relates to method for the treatment of pancreatic cancer in a patient in need thereof comprising a therapeutically effective amount of a Sig-1R ligand.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
UNIVERSITÉ D'AIX MARSEILLE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT JEAN PAOLI & IRENE CALMETTES (France)
UNIVERSITE COTE D'AZUR (France)
Inventeur(s)
Soriani, Olivier
Borgese, Mauro-Franck
Rapetti Mauss, Raphaël
Tomasini, Richard
Abrégé
Pancreatic Ductal Adenocarcinoma (PDAC) still represents a therapeutic dead-end. The inventors report that the K+ channel SK2 is stimulated by secreted cues from cancer-associated- fibroblasts (CAF) leading to the activation of an Integrin-EGFR-AKT signaling axis which participates to the acquisition of pro-metastatic features. The inventors show that SK2 acts as a pivotal signaling regulator as being both a direct target of AKT and an amplifier of AKT- downstream transduction. The present invention relates to a method of treatment of pancreatic cancer in a patient in need thereof comprising a therapeutically effective amount of SK2 inhibitor.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE NORMALE SUPERIEURE (France)
ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (France)
INSTITUTO SUPERIOR TECNICO (Portugal)
FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA (Portugal)
Inventeur(s)
Serre, Christian
Tissot, Antoine
Cao, Chenchen
Luzia Goncalves Pinto, Moisés
Silva, João
Antunes, Fernando
Pinto, Rosana
Abrégé
The present invention belongs to the field of nanoporous materials, in particular metal organic frameworks (MOFs) and Lewis-based gas delivery and/or slow release, or the detection of Lewis-based gas(es) in gases or liquid streams. The present invention relates, inter alia, to a new ultra-microporous crystalline metal organic framework solid ( comprising bisphosphonic acid ligands (also refered to as Phosphonate MOF), such as MIP-210(M) and uses thereof as a carrier in Lewis-based gas (such as NO) delivery. The invention also relates to controlled release of the Lewis-based gas in wounds, for example by topical application. The invention also encompasses a synthetic method for producing the new ultra- microporous crystalline metal organic framework solid of the invention. The MOFs of the present invention can be used in various applications such as gas carrier and/or for the controlled release of gas. The MOFs of the present invention thus are very versatile and have therapeutic and non therapeutic applications.
A61L 15/00 - Aspect chimique des bandages, des pansements ou des garnitures absorbantes ou utilisation de matériaux pour leur réalisation
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
B01D 53/00 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols
B01D 53/94 - Epuration chimique ou biologique des gaz résiduaires des gaz d'échappement des moteurs à combustion par des procédés catalytiques
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Bonduelle, Colin
Harrisson, Simon
Lecommandoux, Sébastien
Badreldin, Mostafa
Le Scouarnec, Rosanna
Abrégé
The present invention concerns an aqueous solution comprising at least one synthetic (co)polymer, wherein said (co)polymer comprises at least one (L)-proline or (D)-proline monomer unit, wherein said (co)polymer exhibits a temperature-driven phase change involving aggregation on heating which is reversible on cooling and has a hysteresis greater than or equal to 20°C.
C08J 3/05 - Production de solutions, dispersions, latex ou gel par d'autres procédés que ceux utilisant les techniques de polymérisation en solution, en émulsion ou en suspension dans un milieux aqueux à partir de polymères solides
C08L 77/04 - Polyamides dérivés des acides alpha-aminocarboxyliques
G01K 11/06 - Mesure de la température basée sur les variations physiques ou chimiques, n'entrant pas dans les groupes , , ou utilisant la fusion, la congélation ou le ramollissement
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE SUPERIEURE DE CHIMIE-PHYSIQUE-ELECTRONIQUE DE LYON (France)
Inventeur(s)
Gay, Isabelle
Barbaroux, Magali
Dufour, Alexandre
Marquette, Christophe
Petiot, Emma
Abrégé
The invention concerns a sterile enclosure (2) intended for a printing of a biological three- dimensional structure, the sterile enclosure comprising : - a rigid top plate (4),5 - a rigid base plate (6) comprising a main face (16) intended to receive a biological three- dimensional structure, - a flexible side wall (8) fixed to the top plate and to the base plate to form an hermetically closed casing (10) delimiting an interior chamber (11), - a puncturable membrane (22) or a needle adapter arranged on the top plate, - a stretcher arm (36) articulated to the top plate and to the base plate, the flexible side wall and the stretcher arm being conform to allow the move of the top plate with respect to the base plate in three perpendicular directions (X,Y,Z); the at least one stretcher arm being elastic and pushing the top plate apart from the base plate.
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (France)
ECOLE SUPERIEURE DE CHIMIE-PHYSIQUE-ELECTRONIQUE DE LYON (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Gay, Isabelle
Barbaroux, Magali
Dufour, Alexandre
Marquette, Christophe
Petiot, Emma
Abrégé
The invention concerns a sterile enclosure (2) and a method of printing and culturing a three-dimensional biological structure in the sterile enclosure. The sterile enclosure comprising: - a base wall (10), - a flexible side wall (8); the side wall forming with the base wall (10) a flexible casing (12) delimiting an interior chamber (14), - a fluid inlet port (22) and a fluid outlet port (24) which allow the circulation of a culture media, - a needle adapter (4) fixed to the flexible side wall (8), the needle adapter (4) holding a printing needle (6), the flexible casing protecting a biological three-dimensional structure against contamination and authorizing at the same time the move of the needle adapter (4) in three directions during a printing of a biological three-dimensional structure in the interior chamber.
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (France)
ECOLE SUPERIEURE DE CHIMIE-PHYSIQUE-ELECTRONIQUE DE LYON (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Gay, Isabelle
Barbaroux, Magali
Dufour, Alexandre
Marquette, Christophe
Petiot, Emma
Abrégé
The invention concerns a sterile enclosure (91) comprising a container (92) and a printing needle holder device (58) fixed to the container. The container comprising a base wall (92), a side wall (94), the side wall and the base wall delimiting an interior chamber, one inlet port and outlet port and an aperture (24). The printing needle holder device (58) comprising a needle adapter, a printing needle and a flexible sheath having a first end edge fixed to the needle adapter and a second end edge fixed to the aperture of the container, a three dimensional biological structure being intended to be printed on the base wall (92), the interior chamber being intended to receive a cell culture media.
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Garden, Jean-Luc
Latargez, Charlotte
Bourgault, Daniel
Moiroux, Gaël
Abrégé
minmaxeffectiveeffective which is comprised between 0.1 and 1.9, ZT being the figure of merit of the microsensor, and T being the measurement temperature.
G01J 5/12 - Pyrométrie des radiations, p.ex. thermométrie infrarouge ou optique en utilisant des détecteurs électriques de radiations en utilisant des éléments thermoélectriques, p.ex. des thermocouples
84.
MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ CLAUDE BERNARD LYON 1 (France)
UNIVERSITÉ DE MONTPELLIER (France)
Inventeur(s)
Bordignon, Benoît
Lescouzères, Léa
Bomont, Pascale
Abrégé
The present invention relates to the field of neuromuscular disorders (NMDs) and corresponding quantification methods. There indeed remains a strong need for novel drugs for the treatment and prevention of neuromuscular disorders. The inventors showed that the compounds according to the invention allow restoring locomotion and cellular related parameters: neuromuscular junctions structure, in particular by improving AChR clustering, and/or by increasing the co-localization of presynaptic nerve terminals and AChR microclusters, and/or by rescuing axonal outgrowth, in an individual with a neuromuscular disorder. In particular, the present invention relates to new compounds suitable for treating and/or preventing a neuromuscular disorder in an individual in need thereof. The present invention also relates to a method for automating the quantification of axons and/or neuromuscular junctions in a whole organism or in a biological sample and to a method for the identification of a compound able to prevent and/or treat a neuromuscular disorder in an individual in need thereof.
A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ TOULOUSE III – PAUL SABATIER (France)
Inventeur(s)
Savignac, Magali
Pelletier, Lucette
Abrégé
Voltage-dependent calcium channels (Cav1) contribute to T-cell activation. The inventors previously showed that Th2 cells co-express Cav1.2 and Cav1.3 calcium channels acting in a non-redundant and concerted way to initiate early TCR-driven calcium influx required for cytokine production and Th2-cell functions. While they have demonstrated that both channels have to be present on the same T-cell to induce allergic asthma, how these channels are regulated under TCR engagement is yet unknown. They investigated the relationship between PKCα and the Cav1.2/Cav1.3 duo channels in Th2 cells. They showed that PKC activation was sufficient to trigger Cav1-dependent calcium response and Th2 cytokine production. Cav1 channels, and especially Cav1.3, expression increased at the cell membrane of Th2 cells upon TCR stimulation and PKCα selectively associated with Cav1.3 upon activation. They showed that PKCα antisense oligonucleotides (PKCα-AS) decreased Th2-cell functions and were beneficial in active and passive models of Th2-mediated airway inflammation induced by OVA. Altogether these results show that PKCα by interacting selectively with Cav1.3 after TCR engagement regulates Cav1.2/Cav1.3 duo-dependent calcium signaling and probably by this way impairs Th2-cell functions and their potential to mediate inflammation.
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE SUPERIEURE DE CHIMIE-PHYSIQUE-ELECTRONIQUE DE LYON (France)
Inventeur(s)
Gay, Isabelle
Barbaroux, Magali
Dufour, Alexandre
Marquette, Christophe
Petiot, Emma
Abrégé
A bioreactor (4) allowing bioprinting inside an interior volume thereof is assembled to form a side wall (SW) extending upwardly from a base provided with a target support (20) for the bioprinting. Once an adapter (5) has been coupled to a bioreactor top portion (4b) to plug a corresponding aperture O4, a biological material depositing end (8) may be maintained in an inserted state, extending through and/or being adapted to be fed via the aperture (O4). A sealed enclosure (E), including the side wall and ports, is formed by a sealing operation to interconnect the base and the top portion (4b). Bioprinting is done by driving from outside the depositing end (8), using variation of said volume, for delivering the biological material on the support (20) and then, a culture and/or maturation phase of the printed tissue may start inside the enclosure (E), without displacement of the printed tissue.
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (France)
ECOLE SUPERIEURE DE CHIMIE-PHYSIQUE-ELECTRONIQUE DE LYON (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Gay, Isabelle
Barbaroux, Magali
Dufour, Alexandre
Marquette, Christophe
Petiot, Emma
Abrégé
The invention concerns a sterile enclosure (2) intended for a printing of a biological three-dimensional structure, the enclosure comprising: - a support (4), - a covering cap (6) comprising a rigid part (22) and a flexible part (24) extending in the prolongation of the rigid part, the covering cap (6) being sealed to the support (4) to delimit an interior chamber (32), at least one portion of the rigid part being a septum (30) adapted to be punctured by a printing needle for printing a biological three-dimensional structure in the interior chamber. The invention also concerns a biological printing device and a method of printing.
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE LORRAINE (France)
Inventeur(s)
Lu, Yuan
George, Jean-Marie
Jaffres, Henri
Crete, Denis
Abrégé
The invention relates to a light emission system (10, 20) of the spin-LED or spin-laser type, comprising: - a stack (STA) comprising an active layer (AL) and transport layers; - an electrode referred to as anode (An) and an electrode referred to as cathode (Cath); - a so-called spin injector device (SID) deposited on the stack and comprising: an assembly of at least one first layer (L1) made of ferromagnetic material (Mfer) and at least one second layer (L2) made of metal material (Mmet), the assembly having a bar structure referred to as Hall bar (HB), a first electrode (EL1) and a second electrode (EL2), referred to as spin electrodes, configured to generate, in the Hall bar, a pulsed current I along the X axis in a first direction or a second direction opposite to the first direction; - the spin injector being configured so as to have magnetisation (M) along Z and so that a reversal of the direction of the current I causes a reversal of the direction of the magnetisation (M), a change in the magnetisation of the spin injector inducing a change in the state of circular polarisation of the light (EL) emitted by the emission system.
H01S 5/062 - Dispositions pour commander les paramètres de sortie du laser, p.ex. en agissant sur le milieu actif en faisant varier le potentiel des électrodes
H01S 5/183 - Lasers à émission de surface [lasers SE], p.ex. comportant à la fois des cavités horizontales et verticales comportant uniquement des cavités verticales, p.ex. lasers à émission de surface à cavité verticale [VCSEL]
89.
IMPROVED DEFLECTOMETRY METHOD AND ASSOCIATED SYSTEM
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Arnoult, Alexandre
Grimaldi, Bastien
Abrégé
The invention relates to a deflectometry method for analysing a reflective surface (S) with a system comprising a display (Disp) and an imaging optical unit (IO), the method comprising the steps of: - A sequentially displaying n light images Ili on the display (Disp), a light image Ili having a binarised light intensity obtained by rasterising the pattern M(x-xi), - B detecting, on the matrix detector (Det), the n images Idi obtained by reflecting the n light images Ili onto the reflective surface (S), - C determining a function referred to as the object absolute phase function (fapS) on the basis of the n detected images Idi, the function g further satisfying the equation: g(k.M) = g(M) with any real k, - D comparing the object absolute phase function (fapS) with an absolute phase function (fapMref) referred to as the reference absolute phase function and deducing information therefrom on the shape of the surface.
G01B 11/25 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer des contours ou des courbes en projetant un motif, p.ex. des franges de moiré, sur l'objet
90.
NEUROMORPHIC CIRCUIT FOR PHYSICALLY PRODUCING A NEURAL NETWORK AND ASSOCIATED PRODUCTION AND INFERENCE METHOD
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PARIS-SACLAY (France)
COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (France)
Inventeur(s)
Bortolotti, Paolo
Anane, Abdelmadjid
Cros, Vincent
Kim, Joo-Von
De Loubens, Grégoire
De Rossi, Alfredo
Abrégé
The invention relates to a neuromorphic circuit (10) for physically producing a neural network. The neuromorphic circuit (10) comprises: - at least one component (26) that is capable of being excited according to a plurality of excitation eigenmodes with a respective population and of having a plurality of excitation configurations, - a unit (28) for configuring the component (26) capable of exciting the component (26) in order to obtain an excitation configuration chosen on the basis of a desired neural network architecture, and - a unit (30) for interrogating the component (26) capable of selectively modifying the populations of first excitation eigenmodes and of measuring the populations of second excitation eigenmodes, the first and second excitation eigenmodes being the excitation modes of the input neurons and the output neurons of the desired architecture, respectively.
G06N 3/067 - Réalisation physique, c. à d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone utilisant des moyens optiques
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ PARIS CITÉ (France)
Inventeur(s)
Canaud, Guillaume
Abrégé
Inventors have first investigated the impact of PIK3CA inhibition in NZBWF1/J mice a model of lymphoproliferative disorders. They randomly assigned 30 females aged of 24 weeks to receive either vehicle (n=15) or alpelisib (n=15) during 4 weeks. At the time of sacrifice, alpelisib treated mice demonstrated significantly reduced spleen size. Flow cytometry analysis revealed that B cells were significantly reduced in alpelisib treated mice and CD8 cells count corrected. They then decided to explore the relevance of alpelisib in MRL/MpJ-Faslpr/J mice (referred here as MRL-lpr), another mouse model of lymphoproliferative disorder. These mice with homozygous Fas mutation usually develop severe lymphadenoproliferation. At the time of sacrifice, MRL-lpr mice treated with alpelisib demonstrated a reduction on their spleen and lymph node sizes. Flow cytometry analysis showed correction of B cells, T cells and other immune cells in peripheral blood mononuclear cells (PBMC), lymph nodes and spleen. The invention relates to a method for treating lymphoproliferative disorder in a subject in need thereof comprising a step of administering the subject with a therapeutically effective amount of a PIK3CA inhibitor.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. loxapine, staurosporine
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (France)
INSTITUT NATIONAL DES SCIENCES APPLIQUÉES DE TOULOUSE (France)
Inventeur(s)
Fernandes, Susana
Moulis, Claire
Bascans, Elodie
Claverie, Marion
Severac, Etienne
Remaud-Simeon, Magali
Abrégé
The subject of the present invention is that of preparing glucosylated mycosporines by means of an enzymatic cascade method using α-transglucosylases and sucrose, and use thereof in particular for their anti-UV properties.
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c. à d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p.ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Jehl, Jean-Philippe
Gauchard, Gérome
Cleymand, Franck
Leroux, Mélanie Maria
Poerio, Aurelia
Abrégé
The invention relates to a muscle membrane intended to be affixed to a muscle of a human or animal body, the membrane being capable of at least partially surrounding the muscle, the muscle comprising fibres covered with an outer tissue, the positioned membrane having a shape that is identical to that of the muscle. The membrane is characterised in that it exhibits anisotropic behaviour so as to reproduce the mechanical behaviour of the muscle, the membrane comprising: - a matrix designed in a biocompatible material having an elasticity similar to that of the outer tissue of the muscle, - one or more reinforcing strips rigidly attached to the matrix, each strip being designed in a biocompatible material having an elasticity similar to that of the fibres it covers and each strip being oriented according to membrane stiffening requirements and according to the expected muscle correction.
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
D01D 5/00 - Formation des filaments, fils ou similaires
B33Y 80/00 - Produits obtenus par fabrication additive
A61F 5/00 - Procédés ou dispositifs d'orthopédie pour le traitement non chirurgical d'os ou articulations; Dispositifs pour donner des soins
94.
PROCESS FOR PREPARING WET CONCRETE COMPOSITIONS AND A METHOD FOR CONTROLLING MIXABILITY, RHEOLOGY AND/OR OPEN TIME OF WET CONCRETE COMPOSITIONS
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Frouin, Laurent
Alfani, Roberta
Myrtja, Erisa
Cruickshank, Matthew
Chaouche, Mohend
Abrégé
Process for preparing a wet concrete composition comprising a step of mixing with water: A. at least one aggregate, B. a binder system, in an amount of 400 Kg per m3of the wet concrete composition or less, preferably less than 370 Kg per m333; wherein said admixture formulation (C.) comprises: (C3) at least one water reducing polymer; (C4) optionally a wetting agent and/or a surfactant; wherein the step of mixing with water is carried out with a water to binder system (B.) weight ratio comprised between 0.2 and 0.4, and more advantageously between 0,25 and 0,35.
C04B 24/26 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
C04B 28/16 - Compositions pour mortiers, béton ou pierre artificielle, contenant des liants inorganiques ou contenant le produit de réaction d'un liant inorganique et d'un liant organique, p.ex. contenant des ciments de polycarboxylates contenant des ciments de sulfate de calcium contenant de l'anhydrite
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CENTRALE LILLE INSTITUT (France)
Inventeur(s)
Ordomsky, Vitaly
Khodakov, Andrei
Zhou, Yong
Abrégé
A process to catalyse a chemical reaction to obtain a product, said process comprising the step of reacting a metal or acid catalyst in a solid state, a substrate and a liquid medium, said liquid medium comprising a liquid metal or a liquid metal alloy, wherein the mass ratio of said liquid metal or liquid metal alloy to said catalyst is at least 0.1. The invention further relates to an heterogenous catalyst system comprising a metal or acid catalyst in a solid state and a liquid metal or liquid metal alloy, wherein said catalyst is in contact with a liquid medium, said liquid medium comprising said liquid metal or said liquid metal alloy, and wherein the mass ratio of said liquid metal or said liquid metal alloy to said catalyst is at least 0.1.
B01J 35/00 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général
B01J 35/12 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général liquides ou fondus
B01J 29/70 - Zéolites aluminosilicates cristallines; Leurs composés isomorphes de types caractérisés par leur structure spécifique non prévus dans les groupes
B01J 23/14 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe du germanium, de l'étain ou du plomb
C07C 29/50 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par des réactions d'oxydation avec formation de groupes hydroxyle uniquement par l'oxygène moléculaire
C07C 67/08 - Préparation d'esters d'acides carboxyliques par réaction d'acides carboxyliques ou d'anhydrides symétriques avec le groupe hydroxyle ou O-métal de composés organiques
C07C 67/40 - Préparation d'esters d'acides carboxyliques par oxydation des groupes précurseurs de la partie acide de l'ester d'alcools primaires
C07C 45/29 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés par oxydation de groupes hydroxyle
C07C 45/28 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés par oxydation de restes —CHx
C07C 45/46 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés par condensation par réactions de Friedel-Crafts
C07C 51/23 - Préparation d'acides carboxyliques, de leurs sels, halogénures ou anhydrides par oxydation avec l'oxygène moléculaire de groupes contenant de l'oxygène en groupes carboxyle
C07C 51/235 - Préparation d'acides carboxyliques, de leurs sels, halogénures ou anhydrides par oxydation avec l'oxygène moléculaire de groupes contenant de l'oxygène en groupes carboxyle de groupes —CHO ou de groupes alcool primaire
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Kriekouki, Ioanna
Galy, Philippe
Pioro-Ladriere, Michel
Abrégé
The present invention relates to an electronic device (1) comprising a silicon-on-insulator strip (100) laterally defined by insulating trenches (106); a first gate (112) supported by the strip; a second gate (114), or a third gate (116), parallel to the strip (100), supported by the strip and being separated from the first gate (112) a first gap (e1) or a second gap (e2); two first semiconductor regions (110), or two second semiconductor regions (108), doped and arranged along and on either side of the second gate (114) or the third gate (116); at least one fourth gate (122A, 122B), or at least one fifth gate (126A, 126B), arranged facing the first gap (e1) or the second gap (e2); and a region (130) for biasing a substrate under the strip.
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 29/423 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative ne transportant pas le courant à redresser, à amplifier ou à commuter
H01L 29/66 - Types de dispositifs semi-conducteurs
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL POLYTECHNIQUE DE TOULOUSE (France)
UNIVERSITE PAUL SABATIER - TOULOUSE III (France)
Inventeur(s)
Azzopardi, Stéphane, Joseph
Le, Thanh Long
Richardeau, Frédéric
Jouha, Wadia
Barazi, Yazan
Rouger, Nicolas
Blaquiere, Jean-Marc
Vinnac, Sébastien
Picot, Mathis
Abrégé
The invention relates to a device (100) for controlling and protecting a power transistor (102), comprising: - a nominal switching circuit (103) for the transistor; - a short-circuit detection circuit (105) which keeps the transistor in the conducting state and detects an increase or decrease in the voltage VGS of the transistor relative to reference voltages representative of a short-circuit of the transistor; - a protection circuit (107) which discharges the gate of the transistor after the detection of a short-circuit; and - a circuit (106) for measuring and controlling the nominal switching circuit, the short-circuit detection circuit and the protection circuit.
H03K 17/0812 - Modifications pour protéger le circuit de commutation contre la surintensité ou la surtension sans réaction du circuit de sortie vers le circuit de commande par des dispositions prises dans le circuit de commande
H03K 17/18 - Modifications pour indiquer l'état d'un commutateur
H03K 17/16 - Modifications pour éliminer les tensions ou courants parasites
98.
METHOD FOR PROTECTION AGAINST OXIDATION OF A COMPOSITE MATERIAL PART COMPRISING CARBON
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CENTRALE LILLE INSTITUT (France)
ECOLE NATIONALE SUPERIEURE DE CHIMIE DE LILLE (France)
UNIVERSITE DE LILLE (France)
Inventeur(s)
Rousseau, Guillaume
Alousque, Fanny
Abrégé
The invention relates to a method for protection against oxidation of a composite material part comprising carbon, said method comprising: - impregnating an internal porosity of the part with an impregnation composition comprising, as percentages by weight: (i) between 1% and 60% of colloidal silica; (ii) between 0.5% and 20% of a flux precursor comprising at least one nitrate of an alkali metal M1; (iii) between 0.5% and 20% of a lattice modifying precursor, comprising at least one nitrate or one oxynitrate of an element M2 which is chosen from metals or lanthanides; and (iv) between 20% and 88% of water; and - carrying out a vitrification heat treatment on the part impregnated with the impregnation composition so as to obtain a glass for protection against oxidation comprising at least silica, an oxide of M1 and an oxide of M2.
C03C 3/078 - Compositions pour la fabrication du verre contenant de la silice avec 40 à 90% en poids de silice contenant un oxyde d'un métal divalent, p.ex. un oxyde de zinc
99.
VOLTAGE/CURRENT OR CURRENT/VOLTAGE CONVERSION SYSTEM
CONSERVATOIRE NATIONAL DES ARTS ET METIERS (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CY CERGY PARIS UNIVERSITE (France)
ECOLE NORMALE SUPERIEURE PARIS-SACLAY (France)
UNIVERSITE PARIS-SACLAY (France)
Inventeur(s)
Bouvet, François
Dupuy, Eric
Ekon, Ayawo, Roger
Petit, Mickaël
Abrégé
The invention relates to a voltage/current or current/voltage conversion system, comprising input terminals (31, 32) and output terminals (41, 42), and between these terminals: a first set (1) and a second set (2), each of these sets comprising at least one switching cell (11, 21), the at least one switching cell of the first set and the at least one switching cell of the second set being associated in pairs so that each switching cell of the first set is associated with a single switching cell of the second set; and a control device which is arranged and/or programmed to send, to the switches of the switching cells, a signal which is arranged to cause the switches to switch between their on state and their off state at the same switching frequency for all the switches so that, for each pair of switching cells, the first switch (111) of the switching cell of the first set of the pair is off when the first switch (211) of the switching cell of the second set of the pair is on, and vice versa.
H02M 1/15 - Dispositions de réduction des ondulations d'une entrée ou d'une sortie en courant continu utilisant des éléments actifs
H02M 3/158 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu sans transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs avec commande automatique de la tension ou du courant de sortie, p.ex. régulateurs à commutation comprenant plusieurs dispositifs à semi-conducteurs comme dispositifs de commande finale pour une charge unique
H02M 1/12 - Dispositions de réduction des harmoniques d'une entrée ou d'une sortie en courant alternatif
100.
DEVICE FOR IMPROVING THE NONLINEAR PROPERTIES OF AN OPTICAL FIBRE AND METHOD FOR IMPROVING THE NONLINEAR PROPERTIES OF AN OPTICAL FIBRE